| US 7,482,124 B2 | ||
| Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema | ||
| Koustubh Ranade, Princeton, N.J. (US); Terrye Aigeldinger Delmonte, Ewing, N.J. (US); and William J. Geese, Doylestown, Pa. (US) | ||
| Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US) | ||
| Filed on Jul. 07, 2006, as Appl. No. 11/483,290. | ||
| Claims priority of provisional application 60/697727, filed on Jul. 08, 2005. | ||
| Claims priority of provisional application 60/706171, filed on Aug. 05, 2005. | ||
| Claims priority of provisional application 60/705995, filed on Aug. 05, 2005. | ||
| Prior Publication US 2007/0009945 A1, Jan. 11, 2007 | ||
| Int. Cl. C12Q 1/68 (2006.01); G01N 33/53 (2006.01) | ||
| U.S. Cl. 435—6 [435/7.21] | 17 Claims |
| 1. A method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral
edema in a patient comprising the step of:
(a) incubating mammalian cells that endogenously express renin with a test compound; and
(b) measuring the level of induced expression of renin mRNA in response to said test compound; wherein a decreased level of induced renin mRNA expression by said test compound relative to a reference compound is indicative
of a decreased risk of said test compound inducing dose-dependent peripheral edema in a patient.
|